S708
Clinical – Lower GI
ESTRO 2026
14 Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 15 Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 16 Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom. 17 Department of Oncology, Rigshospitalet, Technical University Hospital of Greater Copenhagen, Copenhagen, Denmark
whereas worsening of cognitive functioning, diarrhoea, financial difficulties, body image, abdominal and buttock pain showed an inverse correlation with age. Conclusion: Despite often being classified as ECOG 1, older patients in our study demonstrated comparable survival rates and less deterioration in QoL than their younger peers. However, the higher incidence of local recurrence in early-onset and older patients requires further investigation. Female patients experienced greater deterioration in QoL during TNT, as well as a lower cCR/pCR ratio, but no meaningful difference in long-term QoL or survival compared to male patients. Supportive and restaging strategies for female patients should be critically reassessed. Keywords: rectal cancer; clinical trial, Quality of life APHRODITE: A prospective phase II randomised controlled trial of dose-escalated vs standard dose (chemo)radiotherapy in early rectal cancer Simon Gollins 1 , Eleanor M Hudson 2 , Matthew Norris 2 , Monica Jefford 3 , Alwyn Burrage 4 , Claire Arthur 5 , Rebecca Muirhead 6,7 , Ravi Adapala 8 , Simon P Bach 9 , Alexandra Gilbert 10 , Maria Hawkins 11 , Debra Howard 12 , James Iddenden 13 , Rohit Kochhar 14 , Mark Saunders 5 , Mark Teo 15 , Edward JD Webb 16 , Nicholas West 10 , Alexandra Smith 2 , Samantha Noutch 2 , Rebecca Day 2 , Sarah R Brown 2 , David Sebag-Montefiore 10 , Ane L Appelt 10,17 1 Department of Oncology, Shrewsbury and Telford NHS Trust, Shrewsbury, United Kingdom. 2 Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom. 3 Patient Advocate, NA, London, United Kingdom. 4 Patient Advocate, NA, Conwy North Wales, United Kingdom. 5 Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 6 Department of Oncology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 7 Department of Oncology, University of Oxford, Oxford, United Kingdom. 8 Department of Radiology, Wrexham Maelor Hospital, Wrexham, United Kingdom. 9 School of Medical Sciences, University of Birmingham, Birmingham, United Kingdom. 10 Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom. 11 Medical Physics and Biomedical Engineering, University College London, London, United Kingdom. 12 National Radiotherapy Trials QA (RTTQA) Group, Mount Vernon Cancer Centre, Middlesex, United Kingdom. 13 National Radiotherapy Trials QA (RTTQA) Group, Clatterbridge Cancer Center, Liverpool, United Kingdom. Proffered Paper 2319
This abstract is part of the press programme and is embargoed until the congress.
Made with FlippingBook - Share PDF online